Ultragenyx Pharmaceutical (RARE) Other financing activities (2014 - 2025)

Ultragenyx Pharmaceutical (RARE) has 12 years of Other financing activities data on file, last reported at $6.0 million in Q4 2025.

• On a quarterly basis, Other financing activities rose 50.0% year-over-year to $6.0 million in Q4 2025; TTM through Dec 2025 was $17.0 million, a 54.55% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, down 45.45% from the prior year.
• Other financing activities for Q4 2025 stood at $6.0 million, up from $4.0 million in the prior quarter.
• Over the last five years, Other financing activities for RARE reached as high as $40.5 million in Q4 2021 and fell as low as -$25.9 million in Q3 2021.
• Historically, Other financing activities has averaged $4.1 million across 5 years, with a median of $28000.0 in 2023.
• On a YoY basis, Other financing activities climbed as much as 44263.79% in 2021 and fell as far as 239.39% in 2021.
• Year by year, Other financing activities stood at $40.5 million in 2021, then plunged by 98.92% to $436000.0 in 2022, then sank by 93.58% to $28000.0 in 2023, then surged by 14185.71% to $4.0 million in 2024, then soared by 50.0% to $6.0 million in 2025.
• Per Business Quant data, the three most recent Other financing activities figures were $6.0 million in Q4 2025, $4.0 million in Q4 2024, and $7.0 million in Q3 2024.